Long-Term Clinical Outcomes Following Radiofrequency and Microwave Ablation of Renal Cell Carcinoma at a Single VA Medical Center

Publication date: Available online 17 May 2017
Source:Current Problems in Diagnostic Radiology
Author(s): Salim E. Abboud, Tanay Patel, Stephanie Soriano, Joseph Giesler, Nannette Alvarado, Preet Kang
PurposeMWA is a relatively newer treatment modality for treatment of renal cell carcinoma, and only a few small studies have examined the short-and long-term outcomes for MWA applied to renal tumors. The purpose of this retrospective review is to assess the initial experience including technical short- and long-term success rates of using RFA and MWA for RCC at a single VA medical center.Materials and MethodsTumor characteristics were recorded using the R.E.N.A.L. nephrometry score. Group comparisons were performed by using univariate logistic regression analysis to determine factors impacting primary treatment success, failure, and effectiveness. Kaplan-Meier local tumor progression-free survival following ablation was calculated.ResultsMWA and RFA groups were not significantly different in terms of primary treatment success (p =0.82). MWA primary treatment success (90.2 %) was not associated with R.E.N.A.L criteria, while primary success in the RFA group (88.2%) was predicted by smaller tumor size (p =0.002). Primary treatment effectiveness rates were not significantly different in MWA (88.2%) and RFA (80.3%) groups ( p = 0.29). While overall primary technique effectiveness was associated with size (p = 0.02); univariate analysis showed a significant association between tumor size and primary effectiveness for RFA (p = 0.002) but not MWA. There was no significant association between R.E.N.A.L criteria and primary treatment effectiveness in the RFA or MWA groups.ConclusionRFA and MWA both represent effective treatment modalities for RCC; larger tumor size may be associated with decreased efficacy of thermal ablation techniques.



http://ift.tt/2qB0Jur